Introduction {#s1}
============

Schwann cells represent the glial component of the peripheral nervous system. As well as supporting axonal function in a physiological status, they play a critical role during the degenerative and the regenerative processes activated after nerve injury (Namgung, [@B43]; Gordon, [@B20]; Jessen and Mirsky, [@B28]). A severe damage to the nerve tissue determines the loss of axon-Schwann cell contact with subsequent change in Schwann cell phenotype. Schwann cell de-differentiation occurs within 48 h after nerve injury and is driven by changes in gene expression with the down-regulation of genes related to myelination and node organisation, and the up-regulation of regeneration associated genes (RAG), such as growth factor receptors and adhesion molecules (Pereira et al., [@B47]; Jessen and Mirsky, [@B28]). De-differentiated Schwann cells isolate lipid droplets, composed by myelin, and participate to their degradation in the distal nerve. Few days after injury they proliferate and align to form the Büngner bands, a tubular structure that physically supports re-growing axons (Fawcett and Keynes, [@B13]; Ide, [@B25]). Moreover, Schwann cells are the source of growth factors that stimulate axon growth and create the appropriate supportive environment for axonal elongation (Hopker et al., [@B24]; Madl and Heilshorn, [@B36]). In the later phase of the regenerative process, they differentiate into myelinating and non-myelinating Schwann cells, determining the recovery of nerve morphology.

Schwann cell de-differentiation, proliferation and survival are regulated by the action of several growth factors. Among them, Neuregulin 1 (NRG1) increasingly attracted the attention for its involvement in several aspects of Schwann cell behaviour. NRG1 is a growth factor characterised by multiple isoforms thanks to alternative splicing (Mei and Xiong, [@B38]). Both soluble and transmembrane isoforms are present in peripheral nerves: transmembrane isoforms are expressed by neurons and are involved in myelin thickness regulation (Michailov et al., [@B39]; Taveggia et al., [@B56]), whereas soluble NRG1 isoforms are released both by Schwann cells and neurons and are thought to control Schwann cell survival, migration, de-differentiation, as well as the myelination process (Birchmeier and Nave, [@B5]; Fricker and Bennett, [@B17]; Stassart et al., [@B53]). NRG1 is strongly and transiently up-regulated in the distal stump immediately after nerve injury (Carroll et al., [@B7]; Stassart et al., [@B53]; Ronchi et al., [@B48]), suggesting a major role played by it in the response to nerve injury and in the nerve regeneration process.

Despite cellular effects induced by NRG1 stimulation, such as cell survival and migration, have been widely investigated (Dong et al., [@B11]; Zanazzi et al., [@B66]; Atanasoski et al., [@B3]; Birchmeier and Nave, [@B5]; Wakatsuki et al., [@B59]) and single genes have been demonstrated to be regulated by NRG1 in Schwann cells (Freidin et al., [@B16]; Iruarrizaga-Lejarreta et al., [@B26]; Sonnenberg-Riethmacher et al., [@B52]), a deep sequencing analysis of the genes modulated by NRG1 a few hours after stimulation has not yet been performed. Here, we present a global transcriptome analysis, aimed to identify the genes regulated *in vitro* by soluble NRG1 stimulation in primary rat Schwann cell culture.

We chose to analyse the transcriptome 6 h after NRG1 stimulation, to detect the early regulated genes and compare their expression pattern with the genes regulated *in vivo* after injury, where soluble NRG1 release and transcription are induced soon (Carroll et al., [@B7]; Guertin et al., [@B22]; Stassart et al., [@B53]; Ronchi et al., [@B48]; Yu et al., [@B65]) and a strong gene expression regulation is detectable between 6 h and 24 h (Yi et al., [@B63]).

Materials and Methods {#s2}
=====================

Schwann Cell Primary Culture {#s2-1}
----------------------------

To obtain Schwann cell primary cultures, sciatic nerves from adult female Wistar rats (ENVIGO, Milan, Italy) were isolated and harvested. This study was carried out in accordance with the recommendations of the Council Directive of the European Communities (2010/63/EU), the National Institutes of Health guidelines, and the Italian Law for Care and Use of Experimental Animals (DL26/14). The protocol was approved by the Italian Ministry of Health and the Bioethical Committee of the University of Torino. Conformed measures were taken into account to reduce the number of animals used and to minimise animal pain and discomfort.

Schwann cells from sciatic nerves were purified and cultured as previously described (Gnavi et al., [@B19]). Primary Schwann cells were routinely cultured on poly-L-lysine (PLL, Sigma)-coated plate, in complete medium consisting of DMEM (Sigma \#D5671) supplemented with 10% heat-inactivated foetal bovine serum (FBS, Invitrogen), 100 units/ml penicillin, 0.1 mg/ml streptomycin, 1 mM sodium pyruvate, 2 mM L-glutamine, 8 nM recombinant soluble NRG1β1 (\#396-HB, R&D Systems), 10 μM forskolin (Sigma) and incubated at 37°C in 5% CO~2~.

Schwann cells were cultured in the presence of 10 μM forskolin, because Schwann cell primary cultures display dedifferentiated cell features, having lost their axonal contact (Morrissey et al., [@B42]), but they can be induced to reacquire the differentiated phenotype (i.e., high myelin gene expression) by exposure to agents increasing the intracellular levels of cAMP (Sobue et al., [@B51]).

Schwann Cell Stimulation and RNA Isolation {#s2-2}
------------------------------------------

Confluent Schwann cells were starved overnight in starving medium consisting of DMEM (Sigma \#D5671) supplemented with 2% heat-inactivated FBS, 100 units/ml penicillin, 0.1 mg/ml streptomycin, 1 mM sodium pyruvate, 2 mM L-glutamine, and 10 μM forskolin and then stimulated for 6 h with 10 nM recombinant soluble NRG1β1 (\#396-HB, R&D Systems). Control mock samples were stimulated with the same volume of ligand resuspension buffer (PBS containing 1% bovine serum albumin/BSA, Sigma). After the stimulation, total RNA was isolated using TRIzol reagent (Invitrogen), following manufacturer's instructions.

Schwann cell stimulation was performed in biological triplicate for deep sequencing analysis and in biological triplicate for gene expression validation through quantitative real time PCR analysis.

Biological triplicates were carried out using independent preparation of cells.

Deep RNA Sequencing {#s2-3}
-------------------

Deep RNA sequencing was performed on three mock samples and three stimulated samples obtained in three independent experiments. RNA quality was assessed on an Agilent 2100 Bioanalyzer. All samples had RIN ≥9. For RNA-Seq library preparation, approximately 2 μg of total RNA were subjected to poly(A) selection and libraries were prepared using the TruSeq RNA Sample Prep Kit (Illumina) following the manufacturer's instructions. Sequencing was performed on the Illumina NextSeq 500 platform.

The RNA Sequencing data have been deposited in the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO), accessible through GEO Series accession number GSE104324.

Analysis of RNA-Seq Data {#s2-4}
------------------------

Reads were mapped to the *Rattus norvegicus* rn5 reference assembly using TopHat v2.0.10 (Kim et al., [@B30]) and counts were generated using htseq and the refseq transcriptome. Genes with RPKM \>1 in all three replicates were considered expressed in each condition. Differential expression was determined with DESeq2 (Love et al., [@B35]) with default parameters, implementing a paired design by using the biological replicate as covariate. Genes with adjusted *P* ≤ 0.01 and absolute log~2~ fold change \>1 (fold change \<0.5 and \>2) were considered differentially expressed. Gene Ontology enrichment analysis was performed with ClusterProfiler (Yu et al., [@B64]) with a cutoff of *P* adjusted \<0.1 (Supplementary Table [S2](#SM2){ref-type="supplementary-material"}). The analysis was performed using the gene ontology annotation of the mouse orthologs of our genes, due to the better functional annotation of the mouse genome.

Analysis of Public Gene Expression Datasets {#s2-5}
-------------------------------------------

Two gene expression datasets, obtained from injured sciatic nerve samples, were down-loaded from GEO as normalised expression values.

\#GSE22291 series corresponds to microcrushed adult mice sciatic nerves 3 and 7 days after injury, compared with control nerves; samples were hybridised to GeneChip Mouse Genome 430 2.0 Array (Affymetrix), platform GPL1261 (Barrette et al., [@B4]). Genes with adjusted *P* \< 0.001 and absolute log~2~ fold change \>1 were considered differentially expressed.

\#GSE33454 series corresponds to cut adult mice sciatic nerves 1 and 5 days after injury, compared with sham control sciatic nerves; samples were analysed on Illumina MouseRef-8 v2.0 expression beadchip, platform GPL6885 (Kim et al., [@B31]). No biological replicates are available; genes with absolute log~2~ fold change \>1 were considered differentially expressed.

Genes expressed 7 days after adult mice sciatic nerve cut, compared with contralateral uninjured nerves, were downloaded from the Supplementary Material of the article of Arthur-Farraj et al. ([@B2]), where, to generate 100 bp paired-end reads, three libraries were run on a single lane of the HiSeq 2000 platform (Illumina). All selected genes have an adjusted *P* value \< 0.05; those with an absolute log~2~ fold change \>1 were considered differentially expressed.

Genes expressed 0.5 h, 1 h, 6 h, 12 h after adult mice sciatic nerve cut, compared with sham control sciatic nerves, were downloaded from the Supplementary Material of the article of Yi et al. ([@B63]); samples were hybridised to Affymetrix GeneChip Hybridisation Oven 640. Genes with adjusted *P* \< 0.05 and absolute log~2~ fold change \>1 were considered differentially expressed.

cDNA Preparation and Quantitative Real-Time PCR (qRT-PCR) {#s2-6}
---------------------------------------------------------

To validate the deep RNA sequencing analyses, 0.5 μg total RNA were retro-transcribed in a 25 μl reaction volume containing 1× RT buffer, 0.1 μg/μl BSA, 7.5 μM Random Hexamer Primers, 1 mM deoxynucleoside triphosphate (dNTPs), 0.05% Triton, 40U RIBOlock and 200U RevertAid^®^ Reverse Transcriptase (all ingredients were purchased by Thermo Scientific). The reaction was performed following the manufacturer's instructions. qRT-PCR was performed by ABI Prism 7300 (Applied Biosystems, Life Technologies Europe BV) detection system. The cDNA was diluted 10 fold in nuclease-free water, and 5 μl (corresponding to 15 ng starting RNA) were analysed in a 20 μl reaction volume containing 1× iTaq Universal SYBR Green Supermix (BioRad) with 300 nM forward and 300 nM reverse primers. Dissociation curves were routinely performed to confirm the presence of a single peak corresponding to the required amplicon. Analyses were performed in technical and biological triplicate. For each experiment the average of mock samples was used as a calibrator. The threshold cycle (Ct) values were normalised to TATA Binding Protein (TBP), a general RNA polymerase II transcription factor, which has been shown to be a good housekeeping gene without retro-pseudogenes in the genome and with different exons to design forward and reverse primers separated by an intron (Vandesompele et al., [@B58]). Expression data were shown as −ΔΔCT to compare qRT-PCR results with deep sequencing data expressed as log~2~ (fold change). Primers were designed using Annhyb software[^1^](#fn0001){ref-type="fn"} and synthesised by BMR Genomics. Primer sequences are reported in Table [1](#T1){ref-type="table"}.

###### 

List of primers used for quantitative real time PCR (qRT-PCR) analysis to validate deep sequencing results.

  Gene    Accession number   Forward primer (5′--3′)       Reverse primer (5′--3′)      Amplicon size
  ------- ------------------ ----------------------------- ---------------------------- ---------------
  Atf3    NM_012912.2        CACCATCAACAACAGACCTCTGGAG     CCGCCGCCTCCTTTTTCTCTC        85 bp
  Bmp7    NM_001191856.2     CGTCAACCTAGTGGAGCACGAC        GTCACCGCCTCTCCCTCGG          102 bp
  Egr2    NM_053633.1        GACCATCTTCCCCAATGGTGAACTG     GATATGGGAGATCCAAGGGCCTCTTC   119 bp
  Hmga2   NM_032070.1        CGCCACAGAAGCGAGGACG           GGGGCTCTTGTTCTTGCTGCC        113 bp
  Inhba   NM_017128.2        CGGAGATCATCACCTTTGCCGAG       CAGGAAGAGCCAGACTTCTGCAC      116 bp
  Mag     NM_017190.4        CGCCTTCAACCTGTCTGTGGAGT       GCCACGGAGGGTTCCGG            120 bp
  Mbp     NM_017026.2        GGACCCAAGATGAAAACCCAGTAGTCC   CCTTTCCTTGGGATGGAGGGGG       81 bp
  Pmp22   NM_017037.1        CCTTGGGAGCCGTCCAGC            GGACGCTGAAGATGACAGACAGGATC   69 bp
  Shc4    NM_001191065.1     CACTTGGGAAAGGGAGGAGGTCC       CACATCTGCAATGCCGCCTG         112 bp
  Tbp     NM_001004198.1     TAAGGCTGGAAGGCCTTGTG          TCCAGGAAATAATTCTGGCTCATAG    68 bp
  Vegfc   NM_053653.1        CGTCGCCGCCTTCGAGTC            GCTCATCTACACTGGACACAGACCG    122 bp

Statistical Analysis {#s2-7}
--------------------

For qRT-PCR data, statistical analysis between two groups (mock and treated samples) was performed in GraphPad Prism 5 by the two-tailed Student's *t*-test. All data were expressed as mean + standard error (SEM).

Results {#s3}
=======

Several Genes in Schwann Cells Are Regulated By Soluble NRG1 Stimulation {#s3-1}
------------------------------------------------------------------------

To identify the genes regulated early by soluble NRG1, deep sequencing analysis was applied on RNA samples obtained from Schwann cells stimulated 6 h with 10 nM recombinant soluble NRG1β1 (from here on called NRG1) and mock stimulated cells, in three independent biological replicates. Preliminary assays had been previously performed to verify that treatment with 10 nM NRG1 is able to stimulate ErbB3, AKT, ERK phosphorylation (data not shown).

We identified the genes expressed in the biological triplicate by mock Schwann cells (11312, 10810, 11142) and by Schwann cells following NRG1 stimulation (11239, 10811, 11197). Comparing the NRG1 stimulated cells with the mock cells, 190 genes were significantly differentially expressed: 101 up-regulated, 89 down-regulated (with a \|log~2~fold change\|\>1, corresponding to a fold change \<0.5 and \>2, with a P adjusted ≤0.01), with 93% of the differentially expressed genes having an adjusted *P* value \< 0.001.

A heat map of the 50 most differentially regulated genes is shown in Figure [1](#F1){ref-type="fig"}, while the full list of differentially expressed genes is shown in Supplementary Table [S1](#SM1){ref-type="supplementary-material"}.

![Heatmap of the 50 most differentially regulated genes in Schwann cells. The heatmap shows the biological triplicate expression of the first 50 differentially expressed genes in Schwann cells stimulated with 10 nM NRG1β1 based on the obtained *P* value. "Mock" corresponds to samples treated with the vehicle, "treated" corresponds to samples treated with NRG1β1. Colour intensity reflects the expression level and represents the log~2~ (RPKM + 1) of the observed gene in each sample (RPKM, Reads Per Kilo base of transcript per Million mapped reads).](fnmol-11-00157-g0001){#F1}

To validate deep RNA sequencing data, the expression profile of 10 selected genes was analysed by quantitative real time PCR performed on RNA samples obtained from mock Schwann cells or stimulated 6 h with 10 nM NRG1. Validation was performed on three independent biological replicates different from those used for the deep sequencing.

Five up- and five down-regulated genes were chosen based on their adjusted *P* values or their annotated Gene Ontology categories. Among them, eight were strongly regulated (corresponding to 4.2% of differentially regulated genes), two weakly; all of them were significantly validated. Inhba, Hmga2, Bmp7, Shc4, Vegfc were representative for up-regulated genes, Atf3, Pmp22, Egr2, Mag, Mbp were representatives for down-regulated genes. As shown in Figure [2](#F2){ref-type="fig"}, the expression profile of these genes was consistent in both analyses.

![Deep RNA sequencing validation through quantitative real time-PCR (qRT-PCR). Validation of 10 representative gene transcripts was performed by qRT-PCR, showing that the behaviour of five up- and five down-regulated genes was consistent in both techniques. log~2~ fold change (corresponding to −ΔΔCT for qRT-PCR) obtained comparing samples treated with Neuregulin1 (NRG1) with mock treated samples is shown, both for deep sequencing, both for qRT-PCR data.](fnmol-11-00157-g0002){#F2}

NRG1 Strongly Down-Regulates Myelination Genes {#s3-2}
----------------------------------------------

In order to assign the differentially regulated genes to their functions, Gene Ontology analysis was performed using ClusterProfiler package, focusing the attention on the biological processes (BP).

Genes up-regulated following NRG1 stimulation were enriched in two annotation categories: 11 genes belong to the category of "rRNA metabolic processes" (*P*~adj~ = 0.0001), four genes belong to "negative regulation of Notch signalling pathway" (*P*~adj~ = 0.0219); the complete list of these up-regulated genes is shown in Table [2](#T2){ref-type="table"}.

###### 

Biological process (BP) enriched categories obtained by Gene Ontology analysis.

  Biological process enriched category                 Down-regulated genes     *P* adjusted       List of genes
  ---------------------------------------------------- ------------------------ ------------------ -------------------------------------------------------------------------
  Myelination                                          7                        0.004263845        Pmp22, Serinc5, Ndrg1, Fa2 h, Mal, Rxrg, Egr2
  Positive regulation of ion transmembrane transport   6                        0.006544373        Dmd, Hspa2, Snca, P2rx7, Atp1b2, Hcn1
  Glial cell differentiation                           8                        0.008986003        Gpr37l1, Ndrg1, Dmd, Epha4, Fa2 h, Egr2, Ntrk3, Lingo1
  Regulation of membrane potential                     9                        0.010459252        Dmd, Snca, P2rx7, Grik2, Atp1b2, Kcnk5, Cldn19, Slc26a2, Hcn1
  Bleb assembly                                        3                        0.023620351        Emp2, Pmp22, P2rx7
  Positive regulation of apoptotic process             11                       0.080348376        Atf3, Bmf, Gadd45a, Ctsc, Snca, P2rx7, Grik2, Mal, Fbxo32, Ntrk3, Sept4
  Macrophage activation                                3                        0.095570035        Cd200, Snca, Adgrf5
  **Biological process enriched category**             **Up-regulated genes**   ***P* adjusted**   **List of genes**
  rRNA metabolic processes                             11                       0.000126           Fbl, Bop1, Wdr46, Nop56, Ddx21, Nat10, Bysl, Rrp9, Nop2, Emg1, Rrp15
  Negative regulation of Notch signalling pathway      4                        0.02191            Bmp7, Dlk1, Lfng, Dll4

*Because of redundancy in gene ontology annotations, only a selected list of up-regulated and down-regulated biological processes is shown (all enriched categories of biological processes, molecular functions and cellular components are shown in Supplementary Table [S2](#SM2){ref-type="supplementary-material"})*.

Due to redundancy in gene ontology annotations, here we show a selected list of up-regulated and down-regulated BP; the complete list of BP, Molecular Functions (MF) and Cellular Components (CC) is shown in Supplementary Table [S2](#SM2){ref-type="supplementary-material"}.

Functional enrichment is stronger for down-regulated genes. "Myelination" (*P*~adj~ = 0.0043) is the most enriched category among down-regulated genes, with seven genes down-regulated in response to NRG1. The following categories are "Positive regulation of ion transmembrane transport" (*P*~adj~ = 0.0065) with six regulated genes, "Glial cell differentiation" (*P*~adj~ = 0.0090) with eight genes, "Regulation of membrane potential" (*P*~adj~ = 0.0105) with nine genes, "Bleb assembly" with three genes (*P*~adj~ = 0.0236). Finally, "Positive regulation of apoptotic process" (*P*~adj~ = 0.0803) with 11 genes, "Macrophage activation" (*P*~adj~ = 0.0956) with three. The complete list of these down-regulated genes is shown in Table [2](#T2){ref-type="table"}.

Several Genes Regulated By NRG1 Overlap With Genes Regulated Following Nerve Injury {#s3-3}
-----------------------------------------------------------------------------------

As expected, the genes regulated by NRG1 are annotated in categories that are related to Schwann cell response following an injury. To identify which of these genes are also regulated after a nerve injury, expression profiling data obtained from injured sciatic nerve samples were downloaded from GEO or from Supplementary Information of published articles.

To investigate gene expression in the first hours after injury, genes regulated by NRG1 (101 up- and 89 down-regulated) were compared with genes differentially expressed 0.5 h, 1 h, 6 h, 12 h after nerve cut (Yi et al., [@B63]). This analysis shows that after 0.5 and 1 h there are not differentially expressed genes in common with our data. After 6 h, six up-regulated genes are in common, after 12 h, seven up-regulated and two down-regulated genes are in common with our data (Figure [3](#F3){ref-type="fig"}).

![Genes differentially regulated *in vitro* by NRG1 compared with 0.5--12 h injured nerves. Genes significantly regulated following NRG1 stimulation (101 up- and 89 down-) were compared with genes regulated 0.5 h, 1 h, 6 h, and 12 h after sciatic nerve cut (Yi et al., [@B63]). Among them, seven up-regulated and two down-regulated show the same regulation behaviour after 12 h.](fnmol-11-00157-g0003){#F3}

Then, to investigate gene expression in the following phase after injury, genes regulated by NRG1 were compared with genes regulated 1 and 5 days after nerve cut (Kim et al., [@B31]), 3 and 7 days after nerve microcrush (Barrette et al., [@B4]), 7 days after nerve cut (Arthur-Farraj et al., [@B2]). These data show that in the first week of injury 54% of NRG1 down-regulated genes and 40% of NRG1 up-regulated genes are also regulated after nerve injury: 13 up-regulated and 9 down-regulated 1 day after nerve cut; 23 up-regulated and 40 down-regulated 3 days after nerve microcrush; 8 up-regulated and 11 down-regulated 5 days after nerve cut; 16 up-regulated and 26 down-regulated 7 days after nerve microcrush. Many genes show the same regulation at different time points. Intriguingly, few genes (9 up- and 12 down-regulated) show an opposite expression regulation, two genes are down-regulated 1 day after injury and after NRG1 treatment, but later their expression is up-regulated. The complete list of genes regulated both by NRG1 and by nerve injury is shown in Figure [4](#F4){ref-type="fig"}.

![Genes differentially regulated *in vitro* by NRG1 compared with 1--7 days injured nerves. Genes significantly regulated following NRG1 stimulation (101 up- and 89 down-) were compared with genes regulated 1 and 5 days after sciatic nerve cut (Kim et al., [@B31]), 3 and 7 days after sciatic nerve microcrush (Barrette et al., [@B4]), and 7 days (\*) after sciatic nerve cut (Arthur-Farraj et al., [@B2]). Among them, 40 up-regulated and 46 down-regulated show the same regulation behaviour at different time points after injury, 9 up-regulated and 12 down-regulated show an opposite behaviour, two down-regulated genes show a mixed behaviour.](fnmol-11-00157-g0004){#F4}

Discussion {#s4}
==========

Schwann cells, the main glial cells in the peripheral nervous system, play a key role both during development and following nerve injury, being responsible of axonal ensheathment, myelination and post-injury nerve repair (Jessen et al., [@B29]; Taveggia, [@B55]). Different factors and signalling pathways are involved in the control of these activities (Pereira et al., [@B47]; Boerboom et al., [@B6]).

It has been shown by others (Carroll et al., [@B7]; Stassart et al., [@B53]) and our research group (Ronchi et al., [@B48]) that different isoforms of soluble NRG1 are strongly up-regulated after injury. Moreover, in transgenic mice expressing soluble NRG1 in postnatal motoneurons and DRG neurons, but missing NRG1 in Schwann cells (Thy1.2-NRG1-I-β1a X Dhh-Cre X Nrg1^loxP/loxP^), nerve regeneration after crush is inefficient (Stassart et al., [@B53]), thus showing that soluble Nrg1 expressed by neurons does not completely compensate for the lack of NRG1 expression in Schwann cells, thus suggesting that soluble NRG1 plays a key role for their activity after injury.

Schwann cells represent 90% of the total cell number in uncut nerves, 70% in injured nerves, the majority of the rest being fibroblasts, macrophages and perineural cells (Arthur-Farraj et al., [@B2]). The role of the latter must not be denied, but here we focused our attention on Schwann cells, the main non-neuronal cell type in the peripheral nerve, to investigate the role of soluble NRG1 in their activity.

To this aim, by RNA deep sequencing, we carried out a transcriptome analysis to identify the genes regulated *in vitro* in Schwann cells following NRG1 stimulation.

Then, we compared this list of differentially regulated genes with the genes expressed *in vivo* in the injured nerve to find common regulated genes, conscious of the fact that in the injured nerve environment, besides Schwann cells, there are other different cell types, and that there are other released factors besides soluble NRG1.

A stringent analysis was performed to select genes significantly regulated *in vitro* by NRG1 stimulation with a 2-fold threshold and a highly significant adjusted *P* value (≤0.01). As expected, NRG1 stimulation induces differential gene expression in Schwann cells. Applying gene ontology, the regulated genes were categorised into specific groups based on the relevant BP, CC and MF. We focused our attention on the BP; after eliminating redundant categories, down-regulated genes were enriched in seven categories, while up-regulated genes were enriched in two.

Enriched gene categories are consistent with the phenotypic changes occurring in Schwann cells after injury: the portion of the nerve distal to the injury undergoes Wallerian degeneration, a complex process characterised by axonal degeneration and degradation of myelin sheath, followed by debris phagocytosis by Schwann cells and macrophages (Dubovy, [@B12]). Demyelination is an important step during Wallerian degeneration, starting with fragmentation of the myelin sheath into small ovoid-like structures (Ghabriel and Allt, [@B18]) and with the down-regulation of myelin genes (Jessen and Mirsky, [@B27]). Because NRG1 receptor activation is sufficient to initiate Schwann cell demyelination (Guertin et al., [@B22]), it has been suggested that NRG1 might play a key role in the de-differentiation process (Fricker and Bennett, [@B17]; Shin et al., [@B49]).

Both myelinating and non-myelinating (Remak) Schwann cells participate to Wallerian degeneration and trans-differentiate into a repair phenotype specialised to promote nerve regeneration (Jessen and Mirsky, [@B28]). Accordingly, when we consider gene expression analysis *in vivo*, both myelinating and non-myelinating Schwann cells contribute to the transcriptome, as well as *in vitro*, where primary cultures obtained from sciatic nerves contain both myelinating and non-myelinating cells.

When we analysed the enriched categories of differentially expressed genes in response to NRG1 stimulation, we found that "myelination" is the most enriched category among down-regulated genes, with several genes known to be involved in the myelination process down-regulated (Pmp22, Serinc5, Ndrg1, Fa2h, Mal, Rxrg and Krox20/Egr2), thus suggesting that myelination genes were expressed by myelinating Schwann cells undergoing trans-differentiation, while the enriched down-regulated category "glial cell differentiation" reflects gene expression of both myelinating and non-myelinating Schwann cells.

The fact that NRG1 inhibits myelination genes evokes literature data showing that the transcription factor c-Jun negatively regulates myelination (Parkinson et al., [@B44]), down-regulating genes essential in the myelination program, such as the zinc finger transcription factor Krox20/Egr2 (Warner et al., [@B60]), which in turn has been shown to inhibit c-Jun expression in a reciprocal negative feed-back loop (Parkinson et al., [@B45]).

We found that also soluble NRG1 inhibits Krox20/Egr2 expression, thus suggesting that NRG1---inhibiting Krox20/Egr2---might contribute to stimulate c-Jun expression. Accordingly, it has been shown *in vitro* that NRG1 treatment stimulates c-Jun expression (Syed et al., [@B54]) and phosphorylation (Parkinson et al., [@B45]). Further analyses *in vitro* and *in vivo* will be necessary to better investigate the cross-talk between c-Jun and NRG1.

Genes annotated in categories like "positive regulation of apoptotic process" and "bleb assembly" are also down-regulated, suggesting that NRG1 supports Schwann cell survival following nerve injury.

NRG1 stimulation of Schwann cells showed a down-regulation of genes annotated in the enriched category "regulation of macrophage activation", such as Cd200 and Snca. Macrophages are recruited to the nerve injured site to eliminate fragmented myelin debris and dead cells (Dubovy, [@B12]). Cd200 is expressed in node of Ranvier and Schmidt-Lanterman incisures and is down-regulated following nerve injury (Chang et al., [@B9]). It has been suggested that Cd200 down-regulation might facilitate macrophage infiltration through the node of Ranvier to eliminate degenerated axons and myelin debris (Chang et al., [@B9]). Also Synuclein α (Snca) is localised at nodes of Ranvier and Schmidt-Lanterman incisures, is up-regulated during myelination and down-regulated after nerve injury (D'Antonio et al., [@B10]) and might be involved in macrophage infiltration. Indeed, it has been shown that following sciatic nerve transection, transgenic mice over-expressing Snca show a lower number of invading macrophages (Siebert et al., [@B50]).

Two categories of up-regulated genes are enriched in response to NRG1 stimulation: "genes responsible for rRNA metabolic processes" and "negative regulation of Notch signalling pathway". The up-regulation of the former contributes to the synthesis and production of new proteins and molecules needed to guide Wallerian degeneration and nerve regeneration.

Notch is a transmembrane receptor that acts as a negative regulator of myelination: it is down-regulated during myelination and by Krox20, and plays an important role in demyelination in injured nerves (Mirsky et al., [@B40]; Woodhoo et al., [@B61]). For this reason, the up-regulation of negative regulators of the Notch pathway is difficult to explain, unless we hypothesise that Notch is up-regulated in a different time point or that Notch expression is regulated at protein level, or that the genes grouped in this gene ontology category actually contribute to demyelination and Schwann cell de-differentiation without inhibiting Notch pathway. Indeed, Bmp7 retards peripheral myelination by activating p38 MAPK in Schwann cells (Liu et al., [@B34]), while delta like non-canonical Notch ligand 1 (Dlk1) and Delta-like 4 Notch ligand (Dll4) are both Notch ligands.

Since NRG1 is strongly up-regulated after injury and Schwann cells represent a high percentage of cells in the injured nerve, we hypothesised that their contribution to the injured nerve transcriptome is relevant. Therefore, we compared the list of genes regulated in Schwann cells in response to NRG1 stimulation with the lists of genes regulated after nerve injury, with the idea to identify, among many regulated genes, the genes regulated in Schwann cells following NRG1 stimulation.

To this aim, we exploited previously published expression profiling data of injured sciatic nerves at different early time points (0.5, 1, 6, 12 h and 1, 3, 5, 7 days) following injury (Barrette et al., [@B4]; Kim et al., [@B31]; Yi et al., [@B63]). These data were obtained using microarray assay; more recently, deep sequencing data at 7 days after injury were published and made available to the scientific community (Arthur-Farraj et al., [@B2]). Thus, in Figure [4](#F4){ref-type="fig"}, we show two data set corresponding to 7 days after injury; they do not correspond 100%, likely because the first set derives from a microcrushed nerve, the second from a transected nerve; moreover, the first was analysed by microarray, the second was analysed by deep sequencing. Accordingly, the authors of the latter analysis compared their deep sequencing analysis with a previous microarray analysis (Arthur-Farraj et al., [@B1]), finding that \~20% of regulated genes were differently regulated. As expected, several genes that are regulated by NRG1 in Schwann cells overlap with genes regulated in the sciatic nerve following nerve injury. Nevertheless, some genes show a different regulation. These differences can be explained by the fact that genes expressed in injured sciatic nerves belong mainly to Schwann cells, but also to other cell types, while the gene expression profile obtained with the deep sequencing corresponds to genes expressed only by Schwann cells. Moreover, in the injured nerve environment several factors are released, not only soluble NRG1, and the nerve analysis reveals genes regulated by different factors.

*Ex vivo* primary cultures represent a good experimental model as they allow focusing the analysis on a single cell type (e.g., Schwann cells), while *in vivo* different cell types coexist in the injured nerve: Schwann cells, fibroblasts, macrophages, epineural cells, and so on. Moreover, they allow analysing a single factor stimulation (e.g., NRG1), while *in vivo* different factors are released after injury.

Our*in vitro* analysis focused on genes regulated after 6 h stimulation; we chose this time point because we were interested to identify genes regulated early by NRG1 in Schwann cells. Indeed, *in vivo* experiments showed that after nerve injury NRG1 mRNA increase is detectable between 1 h and 24 h (Carroll et al., [@B7]; Stassart et al., [@B53]; Ronchi et al., [@B48]; Yu et al., [@B65]) and several genes start to be differentially expressed between 6 h and 24 h (Yi et al., [@B63]).

By comparing the differentially expressed genes in Schwann cells after *in vitro* NRG1 stimulation with differentially expressed genes in peripheral nerves in response to injury, we found that many genes show the same behaviour in the two experimental models (40% up- and 54% down-regulated) while only 11% show an opposite behaviour. As previously discussed, this opposite behaviour might be explained by the fact that the expression of these genes in the peripheral nerve is not regulated in Schwann cells, but rather in other cell types belonging to the nerve tissue, or by the fact that the expression of these genes in injured Schwann cells is also regulated by other factors released in the injured environment. Among them, we noticed the transcription factors Atf3 and Fos (Patodia and Raivich, [@B46]) and Gadd45a (Lin et al., [@B32]), which are significantly down-regulated by NRG1 in Schwann cells *in vitro*, while *in vivo* are up-regulated in sciatic nerves (Arthur-Farraj et al., [@B2]) and dorsal root ganglia (DRG) neurons after injury.

First, we compared genes differentially expressed *in vitro* in NRG1 stimulated Schwann cells with genes differentially expressed *in vivo* a few hours after nerve injury (0.5--12 h). In the early hours we found more up-regulated than down-regulated common genes. Four of them (Il11, Phlda1, Slc6a17, Vgf) are up-regulated in the first 12--24 h only, thus suggesting that they may play a role immediately after injury.

Then, we focused our attention on up-regulated and down-regulated genes common to all time points (from day 1 until day 7) following nerve injury and following Schwann cell NRG1 stimulation. In this time window, we found more down-regulated than up-regulated common genes.

A common up-regulated gene is Ubiquitin Like with PHD and Ring Finger Domains 1 (Uhrf1), encoding for a E3 ubiquitin ligase. This protein binds to specific DNA sequences, regulating gene expression. It has been shown that Uhrf1 plays a role in inducing basal cell proliferation following airway injury (Xiang et al., [@B62]), thus suggesting that it might play a similar role in stimulating proliferation of Schwann cells following a peripheral nerve injury.

Another common up-regulated gene is Lamin B1 (Lmnb1), playing an important role in the modulation of genes involved in normal myelin regulation; moreover, Lmnb1 over-expression is associated with down-regulation of proteolipid protein, a highly abundant myelin sheath component (Heng et al., [@B23]). Intriguingly, another gene regulated at all time points after injury and after NRG1 stimulation is FXYD domain containing ion transport regulator 5 (Fxyd5), which has been recently shown to be a regeneration-associated gene (RAG), whose over-expression increases (and knock-down decreases) neuritis length and number (Chandran et al., [@B8]).

The common down-regulated genes include Cldn19, Ephx1, Wnt6 and Fa2h.

Tight-Junction Gene Claudin 19 (Cldn19) is the main tight junction constituent of Schwann cells and it is involved in their electrophysiological sealing function (Miyamoto et al., [@B41]) in the healthy nerve. Microsomal epoxide hydrolase (Ephx1) is an evolutionarily highly conserved enzyme expressed in nearly all tissues, where it can play a role in redox homeostasis by removing reactive oxygen species (Václavíková et al., [@B57]). Abnormalities in Ephx1 expression are involved in neurological disorders such as Alzheimer's disease (Liu et al., [@B33]) and tumours. As far as we know, nothing was mentioned in literature about its role in peripheral nerves or Schwann cells.

Wnt is expressed by axons, and it has been found that Wnt signalling promotes Schwann cell lineage progression, proliferation and myelination (Grigoryan et al., [@B21]).

Fatty acid 2-hydroxylase (Fa2h), which is down-regulated from the first till the 7th day post injury, is found to be directly related to the process of myelin formation, where it is required for the synthesis of 2-hydroxy galactolipids in peripheral nerve myelin (Maldonado et al., [@B37]).

Other genes that are down-regulated by NRG1 and related to the myelination process (Mal, Ndrg1, Pmp22, Egr2, Rxrg) are also down-regulated at different time points after injury, suggesting that NRG1 might be involved in the demyelination process following nerve injury.

The down-regulation of genes involved in the myelination is particularly intriguing in the light of our recent data obtained from a rat model of the demyelinating neuropathy Charcot-Marie-Tooth 1A, where we demonstrated that soluble NRG1 is strongly over-expressed in the nerves (Fornasari et al., [@B15]). We wondered if soluble NRG1 over-expression worsens the disease or counteracts it, attenuating its symptoms and promoting nerve repair. The down-regulation of myelination genes suggests that it worsens the disease and that therapeutic approaches aimed to inhibit NRG1 activity could be more useful than therapeutic approaches involving treatment with soluble NRG1 (Fledrich et al., [@B14]). Accordingly, it has been shown that a high concentration of soluble NRG1 negatively affects *in vitro* myelination (Syed et al., [@B54]).

Our *in vitro* analysis shows that soluble NRG1 plays a key role for Schwann cell survival, de-differentiation and demyelination, thus suggesting that *in vivo*, after peripheral nerve injury, soluble NRG1 release or delivery needs to be limited to the early phases after nerve injury. Indeed, in the following phases, the remyelination is promoted by the NRG1 transmembrane isoforms expressed by the axons (Michailov et al., [@B39]; Taveggia et al., [@B56]).

This concept must be kept in mind when planning gene therapies with soluble NRG1 or recombinant factor delivery aimed to promote peripheral nerve regeneration.
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